Loading
Life sciences · Journal article
ESMO Real World Data and Digital Oncology · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Abemaciclib plus endocrine therapy (ET) is an established adjuvant treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC), based on monarchE trial. Prospective real-world data on persistence, adherence, dose management, and patient-reported outcomes (PROs) remain lacking. IT-PATH was designed to address these gaps. Methods IT-PATH is a prospective, multicenter, noninterventional study enrolling patients with HR-positive, HER2-negative high-risk EBC treated with adjuvant abemaciclib + ET at 18 Italian sites. This preplanned interim analysis reports data from the first 100 patients reaching 6-month follow-up. Primary outcome: 6-month treatment persistence and discontinuation rate. Secondary outcomes: adherence [modified medication possession ratio (mMPR)], dose management, safety. Exploratory endpoints (PROs): health-related quality of life (HRQoL), sexual health, and work productivity. Results Patients were 100% female, with a mean age of 55.4 years; 89.6% had Eastern Cooperative Oncology Group Performance Status 0. Treatment persistence at 3 months was 100% and at 6 months was 98% (median follow-up, 5.6 months). Discontinuation occurred in 2% due to adverse events (AEs). Reductions occurred in 52%; high adherence (mMPR ≥0.8 in 89.8%). AEs ≥ grade 3 were reported in 29% (no grade 4/5). Diarrhea (85%), asthenia (38%), and neutropenia (34%) were the most frequent AEs (any grade). No clinically meaningful changes from baseline were observed across all PROs. Conclusions This interim analysis provides prospective real-world evidence that, in routine clinical practice, adjuvant abemaciclib + ET demonstrates feasibility and manageable tolerability with high treatment persistence and no clinically meaningful changes in HRQoL during the first 6 months of therapy. These findings support the value of proactive and personalized dose management to sustain treatment exposure and patient well-being.